Yahoo · Sep 15, 2026
What Makes Acrivon Therapeutics, Inc. (ACRV) a New Buy Stock
Acrivon Therapeutics, Inc. (ACRV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
AC
NASDAQ · ACRV
Acrivon Therapeutics, Inc. Common Stock
Healthcare · Biotechnology
$1.88
Up+$0.02 (+1.08%)
Updated Oct 8, 2026, 2:15 AM
SID Score
5.1/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 47.65M
- P/E ratio
- -0.71
- Dividend yield
- 0.00%
- 52-week range
- $1.27 – $2.39
- Volume
- 283.46K
- Avg. volume
- 1.62M
Price performance · ACRV
ACRV price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 7, 2026
ACRV closed at $1.88 after 21 trading sessions, down 5.53% for the selected period.
- Last close
- $1.88
- Period change
- -5.53%
- Period low
- $1.70
- Period high
- $2.15
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 7, 2026 | $1.85 | $1.9133 | $1.82 | $1.88 | 283.46K |
| Oct 6, 2026 | $2.00 | $2.07 | $1.85 | $1.86 | 158.75K |
| Oct 5, 2026 | $1.99 | $2.035 | $1.91 | $1.98 | 402.17K |
| Oct 2, 2026 | $2.05 | $2.06 | $1.99 | $1.99 | 205.12K |
| Oct 1, 2026 | $2.02 | $2.12 | $2.00 | $2.01 | 316.87K |
| Sep 30, 2026 | $2.09 | $2.16 | $2.04 | $2.05 | 176.93K |
| Sep 29, 2026 | $2.05 | $2.12 | $2.05 | $2.08 | 132.7K |
| Sep 28, 2026 | $2.08 | $2.12 | $2.025 | $2.06 | 231.03K |
| Sep 25, 2026 | $2.12 | $2.13 | $2.07 | $2.10 | 181.95K |
| Sep 24, 2026 | $2.10 | $2.15 | $2.04 | $2.12 | 317.07K |
| Sep 23, 2026 | $2.14 | $2.17 | $2.025 | $2.06 | 435.42K |
| Sep 22, 2026 | $2.04 | $2.24 | $2.01 | $2.15 | 572.48K |
| Sep 21, 2026 | $1.89 | $2.025 | $1.8706 | $2.01 | 334K |
| Sep 18, 2026 | $1.71 | $1.8951 | $1.69 | $1.85 | 478.19K |
| Sep 17, 2026 | $1.74 | $1.77 | $1.67 | $1.70 | 463.84K |
| Sep 16, 2026 | $1.85 | $1.90 | $1.695 | $1.70 | 765.12K |
| Sep 15, 2026 | $1.97 | $1.975 | $1.805 | $1.83 | 304.88K |
| Sep 14, 2026 | $1.98 | $1.99 | $1.94 | $1.96 | 208.34K |
| Sep 11, 2026 | $2.05 | $2.06 | $1.95 | $2.00 | 461.59K |
| Sep 10, 2026 | $2.03 | $2.06 | $1.96 | $2.04 | 323.97K |
| Sep 9, 2026 | $2.10 | $2.17 | $1.99 | $1.99 | 239.12K |
Latest ACRV news
The latest Smart Investors Daily articles mentioning ACRV.
Stock researchCompany · Overview
Company
Market Activity
Research & News
ACRV research
Overview
Company profile and research snapshot.
Company profile
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $21.83
- Implied upside
- —
- Analysts
- 15
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jan 9, 2026 | Piper Sandler | Overweight | — |
| Nov 25, 2025 | HC Wainwright & Co. | Buy | — |
| Aug 14, 2025 | Oppenheimer | Outperform | — |
| May 16, 2025 | Jones Trading | Hold | — |
| May 15, 2025 | Oppenheimer | Outperform | — |
News briefing
No generated briefing is available yet.
Yahoo · Sep 3, 2026
Acrivon Therapeutics, Inc. (ACRV) Just Flashed Golden Cross Signal: Do You Buy?
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
Yahoo · Sep 2, 2026
Acrivon Therapeutics to Present at the 2026 Cantor Global Healthcare Conference
WATERTOWN, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3 (Acrivon Predictive Precision Proteomics) platform deployed for rational drug design and predictive clinical development, today announced the company’s president and chief executive officer, Peter Blume-Jensen, M.D., Ph.D
Yahoo · Aug 31, 2026
Acrivon Therapeutics Appoints Michaela Levin, Ph.D., as Chief Business Officer
Experienced biotechnology executive brings an extensive track record in business development, strategic transactions, licensing and corporate strategyWATERTOWN, Mass., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3 (Acrivon Predictive Precision Proteomics) platform deployed for rational
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
